Ascitic complement system in ovarian cancer

Abstract

Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo. Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor, CD59 and CD46, and the alternative pathway inhibitors factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.

Serum protein signature may improve detection of ductal carcinoma in situ of the breast

“…Subsequent analysis of an independent sample set confirmed an increase of the 8.1 and 8.9 kDa C3a fragments in breast cancer (Li et al, 2005), which was confirmed by a third study (Mathelin et al, 2006). Finally, C3a desArg is not unique to breast cancer and has been shown to be elevated in other cancers, such as ovarian cancer (Bjorge et al, 2005), chronic lymphoid malignancies (Miguet et al, 2006), hepatocellular carcinoma (Lee et al, 2006) and colon cancer (Ward et al, 2006). We also identify, for the first time, PF-4 as Serum protein signature and detection of DCIS J Solassol et al a potential biomarker in early-stage breast cancer.…”

Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration

“…Colon Cancer Cells Produce C5a-The complement system can recognize tumor cells, and complement deposition is observed in different types of tumors (9,15). Cells from some tumor types under serum-free conditions will activate and release C5a.…”

2‐D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins

“…We found chain F; human complement component C3c to be 1.53-fold increased in squamous cell carcinoma sera. Two recent reports have shown that elevated levels of C3a were found in the ascitic fluids of ovarian cancer patients and in patients with chronic hepatitis C/HCV-related HCC [14,15].…”